Welcome to our dedicated page for Dare Bioscience news (Ticker: DARE), a resource for investors and traders seeking the latest updates and insights on Dare Bioscience stock.
Daré Bioscience, Inc. develops and commercializes women’s health therapies across contraception, fertility, vaginal health, and sexual health. Its updates center on XACIATO, DARE to PLAY™ Sildenafil Cream, and investigational programs such as DARE-HPV and DARE-PTB1, an intravaginal ring program for prevention of preterm birth.
Recurring news themes include financial results, company updates, product availability through prescription and 503B channels, FDA and IND-related development milestones, clinical-program disclosures, and non-dilutive funding from government sources. Coverage also reflects Daré’s public reporting on product candidates, trials, financing, and business development.
Daré Bioscience (NASDAQ: DARE) reported financial results for Q1 2022, with cash and cash equivalents of $39.3 million as of March 31, 2022. The company announced the initiation of the DARE-HRT1 Phase 1/2 clinical study in April 2022 and an exclusive global license agreement with Organon for XACIATO™, expected to close in Q2 2022. This agreement includes a $10 million cash payment to Daré and the U.S. commercial launch is anticipated in Q4 2022. However, the company's comprehensive loss increased to $8.4 million compared to $7.3 million in Q1 2021.
Daré Bioscience, Inc. (NASDAQ: DARE) has received a $249,000 grant from NICHD to support research aimed at understanding U.S. women's preferences for long-acting injectable (LAI) contraceptives. The study will survey around 1,000 women aged 18-44 to gather insights on user preferences and characteristics of LAI products. Daré is developing 6- and 12-month contraceptive formulations (ADARE-204 and ADARE-214) in collaboration with Adare Pharma Solutions, aiming to enhance user compliance and effectiveness over current options.
Daré Bioscience, Inc. (NASDAQ: DARE) has scheduled a conference call for May 12, 2022, at 4:30 p.m. ET to discuss its financial results for Q1 2022 and provide a company update. Investors can access the call by dialing (844) 831-3031 in the U.S. or (443) 637-1284 internationally. Daré is focused on women's health innovation with products like XACIATO for bacterial vaginosis and clinical candidates like Ovaprene for contraception. The company emphasizes transparency in communication regarding financials and product developments through various channels.
Daré Bioscience (NASDAQ: DARE) announced that Sabrina Martucci Johnson, its President and CEO, will participate in a panel discussion titled "Femtech: Emerging Technology in Women’s Health" at the Innovations in Women’s Health Business Conference on April 21, 2022, from 4:00-5:00 p.m. ET in Boston, Massachusetts. The panel will explore the integration of technology in addressing unique women’s health needs and feature key innovators in the FemTech sector. Daré focuses on advancing therapeutic products dedicated to women's health, including contraception and sexual health.
Daré Bioscience, Inc. (NASDAQ: DARE) has initiated a Phase 1/2 clinical study for DARE-HRT1, an intravaginal ring delivering bio-identical hormones aimed at treating menopause symptoms. This novel therapy potentially marks the first FDA-approved monthly delivery of combined estradiol and progesterone. The study will span three months and evaluate pharmacokinetics, safety, and symptom relief in 20 post-menopausal women. Previous Phase 1 results have shown promising pharmacokinetic profiles, supporting ease of use and consistent dosing. If successful, DARE-HRT1 could address significant menopausal health needs.
Daré Bioscience, Inc. (NASDAQ: DARE) has entered into a global license agreement with Organon to commercialize XACIATO™ (clindamycin phosphate vaginal gel, 2%), which includes a $10 million upfront payment. The anticipated U.S. launch of XACIATO is set for 4Q-2022. The company reported a comprehensive loss of $38.8 million for the year ended December 31, 2021, with $51.7 million in cash reserves. Daré is also progressing on Ovaprene’s pivotal Phase 3 study and expects topline data from DARE-VVA1 in 2H-2022.
Organon (NYSE: OGN) and Daré Bioscience (NASDAQ: DARE) have entered an agreement for Organon to license global rights to XACIATO, an FDA-approved treatment for bacterial vaginosis (BV) affecting an estimated 21 million U.S. women. The deal includes a $10 million upfront payment to Daré, potential milestone payments of up to $182.5 million, and tiered royalties on net sales. XACIATO is expected to be commercially available in the U.S. in Q4 2022, pending regulatory review. This collaboration aligns with Organon's strategy to enhance women's healthcare options.
Daré Bioscience (NASDAQ: DARE) will host a conference call on March 31, 2022, at 4:30 PM ET to discuss its 2021 financial results and company updates. Investors can join via phone or live webcast, with access details provided. The call is part of the company's commitment to transparency in communicating financial and product-related information. Daré specializes in women's health and has an FDA-approved product, XACIATO, along with various innovative candidates in development, including Ovaprene and Sildenafil Cream.
Daré Bioscience (NASDAQ: DARE) announces participation of President and CEO Sabrina Martucci Johnson at the 2022 Virtual Growth Conference hosted by Maxim Group LLC and M-Vest from March 28-30, 2022. Johnson will join the panel titled “Advances in Women's Health: From Clinical to Commercial” on March 28 at 3:00 p.m. ET and deliver a company presentation available on-demand from March 28 at 9:00 a.m. ET. Archived webcasts will be accessible from April 4-8, 2022, and registration links for the conference and presentations are provided in the PR.
Daré Bioscience, a leading innovator in women’s health, has announced its participation in several upcoming conferences. Notably, Sabrina Martucci Johnson, CEO, will present at the Cowen 42nd Annual Health Care Conference on March 8, 2022, at 1:30 p.m. ET. Additionally, she will engage in a panel discussion at the Therapeutic Area Partnerships Conference on March 8 and participate in the 34th Annual Roth Conference on March 14. The company focuses on advancing therapies in women's health, with products like XACIATO for bacterial vaginosis.